Navigation Links
Ekkyo Presents a Positive Assessment one Year After the Launch of EkkyLite(TM), its New Scar Healing System

MARSEILLE, France, October 8 /PRNewswire/ -- Ekkyo(TM), a photomedicine company that develops first-in-class laser-based systems for skin scar prevention and reduction is presenting today, one year after the commercial launch of EkkyLite(TM), its assessment through some key figures:

    - More than 50 French surgeons have used the EkkyLite(TM) system
    - Almost 200 patients have been treated during surgical operations,
      directly in the operating room
    - 10 French centres are already equipped with the EkkyLite(TM) laser,
      allowing coverage of the main regions in France
    - 8 foreign countries are now working with EkkyLite(TM) through a network
      of distributors

Ekkyo has also set up a national register to log and measure the development of the healing process for each patient treated. This confidential register provides personalised access for each practitioner equipped with an EkkyLite (TM) system, allowing them to register the patients treated and also giving them the possibility of publishing scientific articles related to the results obtained.

"This register is a genuine multicentre database updated in real time," comments Alain Cornil, Ekkyo's CEO.

"The development of EkkyLite(TM), both in France and abroad, confirms the potential of our approach and allows us, in return, to enrich our clinical database," adds Cornil "Thanks to this enlarged palette of users, we will very soon be able to present new clinical results."

In the final quarter of 2009, Ekkyo continues to progress and will present EkkyLite(TM) at a national level and, thanks to its network of distributors at an international level, at the following conventions: 10 October: EkkyLite(TM) will be represented by the Austrian distributor, STRADIS, at a convention organised by Austrian Plastic Surgery Society. Alexandre Capon, reference surgeon, will also speak on the LASH (Laser Assisted Skin Healing) technique during the lunch symposia. 16 October: Portuguese plastic surgery convention in Lisbon. From the 23 to the 27 October: plastic surgery 2009 in Seattle. An international convention bringing together more than 3000 surgeons from all over the world. From the 23 to the 25 November: An undisputed name in the world of plastic surgery, the Societe Francaise de Chirurgie Plastique, Reparatrice et Esthetique (SOFCPRE - French Society of Plastic, Reconstructive and Aesthetic Surgery) is organising its 54th convention this year at the CNIT in Paris. The Ekkyo team will be present on stand number 29 and will have the opportunity to officially announce the results of the clinical study carried out since 2007.

About Ekkyo

Created in 2006, Ekkyo is a photomedicine company that develops and markets first-in-class scar-healing devices to reduce scarring and improve post-surgical comfort.

The first laser-assisted skin healing system and the first product marketed by the company, EkkyLite(TM) assists the surgeon right after the critical moment of wound closure, at the early stage of the skin-healing process. By applying a precisely controlled heat stress early in the inflammatory phase of the skin healing process, EkkyLite(TM) makes possible to stimulate and accurately control the balance between skin repair and regeneration. Results confirm the benefits if this LASH(R) (Laser Assisted Skin Healing) technology: enhanced healing with a significantly reduced scar thus repaired tissue is similar to normal skin in its structure.

By this new approach Ekkyo's ambition is to make laser technology available to all, to surgeons first and tomorrow to all doctors facing skin healing issues, and so to contribute to improve the comfort of the intervention and the quality of life of the 70 million patients who are confronted every year to problems of skin healing.

Based in Aix en Provence, France, Ekkyo has 20 staff members as of September 2009.

More on


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
2. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
3. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009
6. Curemark CEO Presents at Epigenomics Conference
7. Neurocrine Biosciences Presents Elagolix Data
8. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
9. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
10. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
11. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):